secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001213900-25-001249
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada appoints Paul Kelly as COO; amends NEO employment agreements, suspends retention payments
--------------------------------------------------------------------------------

- Paul Kelly named COO effective Jan 1, 2025; salary $476K, target bonus 40%, severance 6 months.
- Amended employment agreements for CEO Traversa, CFO Shenouda, CAO Ence extend option exercisability upon termination.
- NEOs receive no salary increases for FY2025, no cash bonuses or long-term incentive awards for FY2024.
- All further retention payments for NEOs and Kelly suspended until Board approves strategic initiatives.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/0001213900-25-001249-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390025001249/ea0226941-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-001249

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer